Celgene Sr. Scientist, Research Analytics in Cambridge, Massachusetts
Celgene is a global biopharmaceutical company leading the way in medical innovation to help patients live longer, better lives. Our purpose as a company is to discover and develop therapies that will change the course of human health. We value our passion for patients, quest for innovation, spirit of independence and love of challenge. With a presence in more than 70 countries, and growing - we look for talented people to grow our business, advance our science and contribute to our unique culture.
We seek a talented, collaborative inter-disciplinary scientist to empower data-driven decisions by ways of integrative computational analysis of public and private datasets related to autoimmune diseases. This individual will play a key scientific role leveraging innovative computational analysis strategies to extract biological interpretations from high-dimensional immune profiling datasets. Successful candidate will be an important member of the Research Analytics team. Research Analytics is a globally-distributed team within Celgene’s Research Informatics and Knowledge Utilization (RIKU) department, involved in collaborative bioinformatics, computational biology and patient selection research alongside colleagues in the Celgene Research & Early Development (R/ED) organization. The role will align directly with the mission of Inflammation and Immunology Thematic Center of Excellence (TCoE) to leverage cell-type specific biology in advancing a strong therapeutic pipeline across early discovery and translational research programs. .
The role will be responsible for leveraging multiple Consortia in which Celgene is a member of, and executing leading-edge analyses including connecting human-centric molecular profiling with pre-clinical validation, deriving precision medicine strategies based on patient variations, multi-omic analyses to pinpoint cell-specific pathways, etc. In addition, successful candidates are expected to be a thought leader in identifying relevant new data resources, deriving computational methodologies, and drive subsequent integration to inform drug discovery and development efforts.
The position would suit an individual with strong scientific leadership potential and collaboration skills. Applications are encouraged from those looking to translating well-focused omics profiling to impact delivery of truly innovative and life-changing therapies. Strong interest in the inter-disciplinary application of computational analysis methods to life sciences data is imperative, as is rich background and experience in neuroscience research.
Working in collaboration with computational, biological and clinical scientists across the Celgene Research and Early Development organization, responsibilities include but are not limited to:
· Pursuit of leading computational biology research towards key Celgene scientific objectives, in a dynamic matrix environment.
· Active participation as a core team member in the I&I Thematic Center of Excellence (TCoE).
· Coordinated application of novel computational analysis and biological interpretation approaches to leverage internal, public and partner datasets and empower data-driven decisions across therapeutic programs.
· Multi-disciplinary collaboration to investigate compound and disease properties and influence decisions from target prioritization.
· Data integration across assay platforms and knowledge transfer from pre-clinical experiments to actionable translational hypotheses.
· Participation in and oversight of scientific report writing. Presentation of methods, results and conclusions to a publishable standard.
· Contribution to planning and execution of collaborative projects with leading academic and commercial research groups worldwide.
Background experience & complementary knowledge
· A Ph.D. in genetics, computational biology, bioinformatics, or related field from a recognized higher-education establishment.
· 5+ years post-doctoral experience of inter-disciplinary computational and autoimmunity research in university, hospital or biotechnology environments.
· 3+ years experience in pharma/biotech research environment preferable.
· Expertise covering 1 or more areas in single-cell analyses, transcriptomics, proteomics, CyToF, ATAC-seq, ChIP-seq.
· Track-record of mechanistic interpretation using integrative pathway analyses highly desirable.
· Previous experience of research supervision and track record of peer-reviewed publication in relevant scientific journals.
· Expertise in algorithmic implementation, statistical programming and data manipulation, using e.g. R/Bioconductor, Matlab, Python, and contemporary, open-source bioinformatics tools and database structures.
· Proven problem-solving skills, collaborative nature and adaptability across disciplines.
Excellent verbal and written communication skills. Fluent verbal and written English language skills prerequisite.
Celgene is committed to equal opportunity in the terms and conditions of employment for all employees and job applicants without regard to race, color, religion, sex, sexual orientation, age, gender identity or gender expression, national origin, disability or veteran status. Celgene complies with all applicable national, state and local laws governing nondiscrimination in employment as well as employment eligibility verification requirements of the Immigration and Nationality Act. All applicants must have authorization to work for Celgene in the U.S.COMMITTED TO IMPROVING THE LIVES OF PATIENTS WORLDWIDE
At Celgene, we seek to deliver truly innovative and life-changing drugs for our patients. Our vision as a company is to build a major global biopharmaceutical corporation while focusing on the discovery, the development, and the commercialization of products for the treatment of cancer and other severe, immune, inflammatory conditions.
“At Celgene, we seek to deliver truly innovative and life-changing drugs for our patients.”
There are more than 300 clinical trials at major medical centers using compounds from Celgene. Investigational compounds are being studied for patients with incurable hematological and solid tumor cancers, including multiple myeloma, myelodysplastic syndromes, chronic lymphocytic leukemia (CLL), non-Hodgkin’s lymphoma (NHL), triple-negative breast cancer and pancreatic cancer. As committed as we are to clinical accomplishment, we are equally committed to patient support, which is a guiding principle at Celgene. We believe all who can benefit from our discoveries should have the opportunity to do so. Celgene puts patients first with industry-leading programs that provide information, support and access to our innovative therapies.